Protagonist (PTGX) news
Recent news
Protagonist Therapeutics, Inc.: H.C. Wainwright raises target price to $170 from $167
AInvest Wire · 5h agoJefferies lifts its Protagonist Therapeutics price target to $171, up from $169.
Jefferies has raised its price target for Protagonist Therapeutics (PTGX) to $171, an increase from the previous $169, reflecting a positive outlook on the company’s recent developments and pipeline progress. The adjustment comes amid growing analyst optimism, with 14 analysts currently rating the…
AInvest Wire · 13h agoJP Morgan raises target price to $149 from $113 for Protagonist Therapeutics, Inc.
JPMorgan has raised its price target for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $149 from $113, maintaining an Overweight rating on the stock . The adjustment follows discussions with the company’s CEO, who highlighted progress in Protagonist’s partnership with Johnson & Johnson on the…
AInvest Wire · Aug 10, 2026H.C. Wainwright raises target price to $167 from $117 for Protagonist Therapeutics, Inc.
AInvest Wire · Aug 6, 2026Citigroup raises target price to $175 from $130 for Protagonist Therapeutics, Inc.
Citigroup has raised its price target for Protagonist Therapeutics, Inc. (NASDAQ: PTGX) to $175 from $130, maintaining its "Buy" rating for the stock, according to recent updates on PTGX . This adjustment reflects the firm’s increased confidence in the company’s growth trajectory and the…
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.